Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Ciardiello

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trialD Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM studyD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trialD Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2012
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision makingH J Schmoll, E Van Cutsem, A Stein, et al.
ESMO Open|March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2016
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerE Van Cutsem, A Cervantes, R Adam, et al.
ESMO Open|August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trialE Martinelli, C Cardone, T Troiani, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trialD Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM studyD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trialD Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2012
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision makingH J Schmoll, E Van Cutsem, A Stein, et al.
ESMO Open|March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2016
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerE Van Cutsem, A Cervantes, R Adam, et al.
ESMO Open|August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trialE Martinelli, C Cardone, T Troiani, et al.
Pageof 19